162 related articles for article (PubMed ID: 37988640)
1. Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.
Hu S; Chang CP; Snyder J; Deshmukh V; Newman M; Date A; Galvao C; Porucznik CA; Gren LH; Sanchez A; Lloyd S; Haaland B; O'Neil B; Hashibe M
JCO Clin Cancer Inform; 2023 Sep; 7():e2300083. PubMed ID: 37988640
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable-risk prostate cancer.
Huang D; Ruan X; Huang J; Zhang N; Jiang G; Gao Y; Xu D; Na R
Cancer Med; 2023 Apr; 12(8):9868-9878. PubMed ID: 36727535
[TBL] [Abstract][Full Text] [Related]
3. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
4. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
Mahal AR; Butler S; Franco I; Muralidhar V; Larios D; Pike LRG; Zhao SG; Sanford NN; Dess RT; Feng FY; D'Amico AV; Spratt DE; Yu JB; Nguyen PL; Rebbeck TR; Mahal BA
Cancer; 2019 Oct; 125(19):3338-3346. PubMed ID: 31251398
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
6. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
9. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations.
Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309
[TBL] [Abstract][Full Text] [Related]
10. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015.
Butler SS; Loeb S; Cole AP; Zaslowe-Dude C; Muralidhar V; Kim DW; Schaeffer EM; Trinh QD; Nguyen PL; Mahal BA
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):179-183. PubMed ID: 31591454
[TBL] [Abstract][Full Text] [Related]
11. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
12. The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database.
Yuan QM; Lin TH; Jin K; Qiu S; Zhou XH; Jin D; Li JK; Yang L; Wei Q
Asian J Androl; 2022; 24(3):305-310. PubMed ID: 34596600
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy versus watchful waiting for prostate cancer.
Hegarty J; Beirne PV; Walsh E; Comber H; Fitzgerald T; Wallace Kazer M
Cochrane Database Syst Rev; 2010 Nov; (11):CD006590. PubMed ID: 21069689
[TBL] [Abstract][Full Text] [Related]
14. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
15. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
16. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
17. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
19. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
20. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
